ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX ...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...

ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support ...

ImmunityBio Inc. IBRX stock is up during Wednesday’s premarket session as the company is gaining attention following the ...

ImmunityBio (IBRX) stock is in focus as the firm licenses U.S. rights to Tokyo-172 BCG for bladder cancer after Phase 3 data showed its potential. Read more here.

After more than doubling its share price in just five days last week, ImmunityBio’s stock rocketed higher again today, finishing up 17%. The catalyst for this was the company’s FDA End-of-Phase ...